A bacteria-based assay to study SARS-CoV-2 protein-protein interactions

Running title: Bacteria-based SARS-CoV-2 protein interactome

Benjamin L. Springstein^{1#}, Padraig Deighan¹, Grzegorz Grabe¹, Ann Hochschild^{1#}

¹ Department of Microbiology, Harvard Medical School, Boston, MA 02115, USA

Corresponding authors:

ahochschild@hms.harvard.edu

benjamin_springstein@hms.harvard.edu

Abstract

Methods for detecting and dissecting the interactions of virally encoded proteins are essential for probing basic viral biology and providing a foundation for therapeutic advances. The dearth of targeted therapeutics for the treatment of COVID-19, an ongoing global health crisis, underscores the importance of gaining a deeper understanding of the interactions of SARS-CoV-2-encoded proteins. Here we describe the use of a convenient bacteria-based two-hybrid (B2H) system to analyze the SARS-CoV-2 proteome. We identify sixteen distinct intraviral protein-protein interactions (PPIs), involving sixteen proteins. We find that many of the identified proteins interact with more than one partner. We further show how our system facilitates the genetic dissection of these interactions, enabling the identification of selectively disruptive mutations. We also describe a modified B2H system that permits the detection of disulfide bond-dependent PPIs in the normally reducing *Escherichia coli* cytoplasm and we use this system to detect the interaction of the SARS-CoV-2 spike protein receptor-binding domain (RBD) with its cognate cell surface receptor ACE2. We then examine how the RBD-ACE2 interaction is perturbed by several RBD amino acid substitutions found in currently circulating SARS-CoV-2 variants. Our findings illustrate the utility of a genetically tractable bacterial system for probing the interactions of viral proteins and investigating the effects of emerging mutations. In principle, the system could also facilitate the identification of potential therapeutics that disrupt specific interactions of virally encoded proteins. More generally, our findings establish the feasibility of using a B2H system to detect and dissect disulfide bond-dependent interactions of eukaryotic proteins.

Importance

Understanding how virally encoded proteins interact with one another is essential in elucidating basic viral biology, providing a foundation for therapeutic discovery. Here we describe the use of a versatile bacteria-based system to investigate the interactions of the protein set encoded by SARS-CoV-2, the virus responsible for the current pandemic. We identify sixteen distinct intraviral protein-protein interactions, involving sixteen proteins, many of which interact with more than one partner. Our system facilitates the genetic dissection of these interactions, enabling the identification of selectively disruptive mutations. We also describe a modified version of our bacteria-based system that permits detection of the interaction between the SARS-CoV-2 spike protein (specifically its receptor binding domain) and its cognate human cell surface receptor ACE2 and we investigate the effects of spike mutations found in currently circulating SARS-CoV-2 variants. Our findings illustrate the general utility of our system for probing the interactions of virally encoded proteins.

Introduction

The causative agent of COVID-19, SARS-CoV-2, like SARS-CoV (hereafter SARS-CoV-1) and the Middle East respiratory syndrome coronavirus (MERS-CoV), is a zoonotic pathogen that belongs to the genus of β -coronaviruses [1,2]. A ~30 kb single stranded (+)-sense RNA virus, SARS-CoV-2 encodes 16 non-structural proteins (Nsp1-Nsp16), which are transcribed from two major open reading frames (ORF1a and ORF1b) and later post-translationally processed by proteases to give rise to the individual Nsps [3]. The main function of the Nsps is to provide and maintain the replication and transcription complex (RTC), promoting viral RNA synthesis by the RNA-dependent RNA polymerase Nsp12 [3]. However, the Nsps have also been implicated in other viral processes such as host innate immune system evasion – for example, by suppressing aspects of the interferon response [4]. The virus also encodes four structural proteins, the membrane (M) protein, the nucleocapsid (N) protein, the envelope (E) protein and the spike (S) glycoprotein, and at least six accessory proteins (ORF3a, ORF6, ORF7a, ORF7b, ORF8 and ORF10) [5]. The main function of coronavirus structural proteins is to mediate cell entry, virus particle assembly and release from the host cells by budding, though like the Nsps, structural proteins also participate in immune evasion. By contrast, the accessory proteins are non-conserved and highly variable among different coronavirus species; although their functional roles remain largely unknown, they too have been associated with immune evasion and disease severity [3].

Given the ongoing global crisis caused by the SARS-CoV-2 pandemic and the continuing need for targeted therapeutics for the treatment of COVID-19, understanding the intraviral and viral-host protein-protein interactions (PPIs) of SARS-CoV-2 remains a priority. An extensive virus-virus and host-virus PPI study recently highlighted the importance of Nsp10 as a potential inducer of the so-called cytokine storm (a dysregulated and hyperactive immune response) [6], thought to be the main cause for severe disease outcome and death in COVID-19

patients [2]. Li *et al.* (2021) further identified Nsp8 as a SARS-CoV-2 PPI hub [6], promoting interactions with other Nsps, accessory proteins, and one structural protein. Similar observations were previously also obtained for SARS-CoV-1 Nsp8 [7]. These findings suggest that Nsp8 and Nsp10 might provide particularly efficacious targets for drug development.

The SARS-CoV-2 spike protein, which is present on the viral surface as trimers, consists of two functionally distinct subunits, S1 and S2 [8,9]. The membrane-distal S1 subunit uses its receptor-binding domain (RBD) to initiate the process of viral entry into human host cells by binding to the cell surface protein angiotensin-converting enzyme 2 (ACE2), which also serves as the receptor for SARS-CoV-1 but not for the more distantly related MERS-CoV. Following ACE2 binding, the membrane-localized host cell serine protease TMPRSS2 cleaves the spike protein at a specific site, triggering a series of dramatic conformational changes in the S2 subunit, which in turn mediate fusion of the viral and host membranes, enabling viral entry [10]. As well as being a critical determinant of viral tropism, the RBD is a major target for SARS-CoV-2-neutralizing antibodies, including those identified from convalescent patient peripheral blood mononuclear cells and those elicited by current (spike-based) vaccines [9,11–18].

Compared with those of other RNA viruses, the mutation rate of SARS-CoV-2 is considered low-moderate ($6\text{--}9 \times 10^{-4}$ bases/genome/year) [19–21], although others have pointed out that multiple identical mutation hotspot events occurring at different points in time could lead to an underestimation of the overall mutation rate [22]. Nevertheless, the pandemic has given rise to a proliferation of variant lineages, including those designated variants of concern (VOCs) by the World Health Organization (WHO), based on one or more of the following criteria: increase in transmissibility; increase in virulence; decrease in effectiveness of public health measures, diagnostics, therapeutics or vaccines (www.who.int/en/activities/tracking-SARS-CoV-2-variants). All of the VOCs carry spike mutations, including one or more that localize to the

RBD, motivating efforts to gain a systematic understanding of the effects of RBD amino acid substitutions on ACE2 binding [23].

Here we employ a bacterial two-hybrid (B2H) system [24,25] to study the PPIs of SARS-CoV-2 in a heterologous non-eukaryotic system. Using this system, we describe a bacteria-based intraviral interactome. We further demonstrate the utility of the bacterial system for genetically dissecting the SARS-CoV-2 PPIs by identifying mutations that selectively affect one or another interaction. In addition, we describe a modified B2H system that allows us to detect disulfide bond-dependent PPIs in the otherwise reducing *Escherichia coli* cytoplasm. We use this system to detect the spike RBD-ACE2 interaction and to investigate the effects of mutations found in VOCs. Our findings set the stage for further investigations of viral PPIs in a convenient and genetically tractable bacterial system, as well as establishing the feasibility of using our modified system to detect and dissect disulfide bond-dependent PPIs of other eukaryotic proteins.

Results

Bacterial two-hybrid system to detect interactions of SARS-CoV-2 proteome

Previous studies have used yeast two-hybrid (Y2H) systems, a mammalian two-hybrid system and co-immunoprecipitation experiments (co-IPs) to investigate the SARS-CoV-1 and SARS-CoV-2 protein interactomes, identifying overlapping but also distinct interactions depending on the employed system [6,7,26,27]. Compared with bacteria, yeast have a relatively slow growth rate and are more difficult to culture and transform for labs that do not routinely work with yeast. To provide a more accessible alternative to Y2H systems as well as the less commonly used mammalian two-hybrid system, we here describe the successful use of a B2H system developed in our lab (Fig. 1A) [24,25] to test for viral PPIs. We fused all NCBI-predicted *E. coli*

codon-optimized SARS-CoV-2 open reading frames (ORFs; listed in Fig. 1B, see also NCBI accession #: NC_045512.2) to the DNA binding protein CI of bacteriophage λ (λ CI) and to the N-terminal domain of the α subunit (α NTD) of RNA polymerase (RNAP). We then tested each SARS-CoV-2 ORF for interaction with the other SARS-CoV-2 ORFs and itself. Interaction between two given ORFs (X and Y), fused to α NTD and λ CI, respectively, stabilizes the binding of RNAP to the test promoter such that the magnitude of the *lacZ* reporter gene expression correlates with the strength of the PPI (Fig. 1A).

Identification of the SARS-CoV-2 interactome using a B2H system

Using our B2H system, we initially tested each SARS-CoV-2 ORF against each other SARS-CoV-2 ORF and itself in biological duplicate. Protein pairs with at least a 2-fold activation of *lacZ* over background in one of the replicates were selected for further analysis. The list of interacting proteins was further refined by performing repeat experiments with three biological replicates for each initially identified potential PPI pair. This resulted in a final list of sixteen interacting SARS-CoV-2 protein pairs, including four self-interactions (Fig. 2). Some of these interactions were identified only with a specific fusion partner combination (*i.e.*, protein X fused to α NTD and protein Y fused to λ CI, or the other way around), while others were fusion partner-independent (*i.e.*, interaction between proteins X and Y regardless of their fusion to α NTD or λ CI). Self-interacting proteins (Nsp7, Nsp9, ORF6 and ORF10) were by definition fusion partner-insensitive; however, four other pairs of proteins (Nsp7+Nsp8, Nsp10+Nsp14, Nsp10+Nsp16, Nsp3+N, and Nsp8+ORF6) also interacted detectably regardless of the fusion partner (Supplementary Fig. 1).

Among the identified interacting pairs, several particularly strong PPIs were observed, including the Nsp7 self-interaction, Nsp7+Nsp8, Nsp10+Nsp16, N+Nsp3 and Nsp9+Nsp11 (Fig. 3). In fact, the Nsp10+Nsp16 pair interacted significantly more strongly than our positive control,

representing one of the strongest interactions we have ever measured with our B2H assay. For our B2H assays, we routinely consider an interaction to be reliable when we detect at least a two-fold increase in *lacZ* reporter gene expression (measured as β -galactosidase activity) over the background (obtained with the negative controls). Applying this cut-off to our experimental data, we identified several medium-to-weak interactions (2- to 5-fold increase over the negative controls; Supplementary Fig. 2). The interactions of Nsp8+ORF7b and ORF10+ORF10 closely missed the 2-fold cutoff but were nonetheless included in the list because a previous SARS-CoV-2 interactome study also identified those interactions (based on co-IP data) [6].

Comparison of our SARS-CoV-2 B2H data with the previously reported SARS-CoV-2 Y2H and co-IP data [6] revealed four PPIs that were shared among the three assay systems, providing strong support for their biological relevance (Supplementary Fig. 3). These included Nsp7+Nsp8, Nsp8+ORF10, Nsp10+Nsp14 and ORF6+ORF6. Others were identified either in only one of the assay systems (*i.e.*, B2H, Y2H or co-IP) or in two assay systems (B2H and Y2H, B2H and co-IP, or Y2H and co-IP) (Supplementary Fig. 3). Furthermore, some of our identified interactions are validated by co-crystal structures. These included Nsp7+Nsp8 (Protein Data Bank (PDB) accession number 6YHU [28]), Nsp10+Nsp14 (PDB: 5NFY from SARS-CoV-1 [29] or more recently 7DIY from SARS-CoV-2 [30]), Nsp10+Nsp16 (PDB: 6W4H [31]) and the Nsp9 self-interaction (PDB: 6W9Q [32]). Notably, no self-interaction of Nsp9 was identified in a previous Y2H and co-IP analysis of the SARS-CoV-2 interactome [6], highlighting the importance of employing several different interaction assays when studying the interactome of a given protein set to avoid loss of information due to experimental system idiosyncrasies.

Similar to previous observations for SARS-CoV-1 [7], we identified Nsp8 as a major SARS-CoV-2 interaction hub, interacting with six other SARS-CoV-2 ORFs (Fig. 3, Supplementary Fig. 2), consistent with a critical role for Nsp8 in SARS coronavirus biology. Nonetheless, most of the interaction partners we identified for Nsp8 in SARS-CoV-2 are

different than those identified previously for SARS-CoV-1 [7,26,27] (Supplementary Fig. 4). Overall, only six PPIs were identified in our SARS-CoV-2 B2H analysis and at least one of three independent SARS-CoV-1 Y2H studies, including two involving Nsp8 (Supplementary Fig. 4). Notably, there are considerable differences between the results of the three previous Y2H studies [7,26,27] and only three PPIs (Nsp8+Nsp7, Nsp10+Nsp14, and Nsp10+Nsp16) were independently identified in two SARS-CoV-1 two-hybrid assays and our SARS-CoV-2 B2H assay (Supplementary Fig. 4). This could reflect significant differences between the PPI networks in SARS-CoV-1 and SARS-CoV-2 and/or differences in the assays themselves (procedures and background organism).

Targeted mutational screens identify interaction partner-specific sites of protein-protein interaction in CoV-2 proteins with more than one interaction partner

As a genetic assay, the B2H system facilitates the dissection of specific PPIs through both targeted and random mutagenesis. Having established the utility of the B2H assay in testing for viral PPIs, we next sought to use this assay to dissect the interactions of selected viral proteins through targeted mutational analysis. Specifically, we chose proteins that interacted with more than one partner and sought to disrupt the interaction of such a protein with one of its partners while preserving its interaction with another. We initially selected Nsp10 with two known interaction partners, Nsp14 and Nsp16, and attempted to disrupt only its interaction with Nsp14. To identify suitable targets for mutagenesis, we analyzed the crystal structures of Nsp10-Nsp14 (PDB ID: 5NFY [29]) and Nsp10-Nsp16 (PDB ID: 6W4H [31]) and their protein-protein interfaces using PDBePISA [33]. Based on this approach, we selected three sets of amino acid substitutions likely to affect the binding of Nsp10 to Nsp14, while leaving its interaction with Nsp16 intact (assuming that the substitutions do not result in allosteric effects). While the Nsp10 F16A/F19A/V21A set targeted the hydrophobic region, the Nsp10 T5A/T12A/S15A and S29A/S33A sets partially disrupted the hydrogen bond network of the Nsp10-Nsp14 interface

(Fig. 4A,C). Each of the three multiply substituted Nsp10 mutants lost the ability to interact detectably with Nsp14 while maintaining an approximately wild-type interaction with Nsp16 (Fig. 4B). We note that the close approach of amino acid side chains at a protein-protein interface as revealed by X-ray crystallography does not necessarily indicate that they participate in a functionally important interaction. However, the loss of a detectable interaction between each of the three Nsp10 mutants and Nsp14 in our B2H assay suggests that at least a subset of the selected residues make stabilizing contacts. Furthermore, although the Nsp10-Nsp16 interaction serves as a control, we also confirmed that the introduced amino acid substitutions were not generally destabilizing (Supplementary Fig. 5).

We then focused on Nsp16 with two interaction partners, Nsp10 and Nsp15, targeting the Nsp16-Nsp10 pair, which displayed a significantly higher B2H signal than that of the Nsp16-Nsp15 pair. Here we also utilized the available crystal structure for the Nsp16-Nsp10 complex; however, as there is no structure for the Nsp16-Nsp15 complex, the substitutions introduced into Nsp16 were based solely on their predicted effects on its interaction with Nsp10. Endeavoring to disrupt the Nsp16-Nsp10 interaction, we created two Nsp16 triple substitution mutants, targeting hydrophobic (I40A/M41A/V44A) or hydrophilic (K76A/Q87A/D106A) contacts, and a mutant with the six substitutions combined (Fig. 4C). The data reveal drastic effects of these substitutions on the binding of Nsp16 to Nsp10, resulting in near background or background levels of reporter gene expression for each of the mutants (Fig. 4D). The effects of the same substitutions on the binding of Nsp16 to Nsp15 were modest and not statistically significant. Notably, even though Nsp16 interacts much more weakly with Nsp15 than with Nsp10, reporter gene expression was lower for each of the Nsp16 mutants in combination with Nsp10 than when tested in combination with Nsp15 (Fig. 4D). We also confirmed that these effects are not the result of altered protein levels (Supplementary Fig. 6). Together, these data

illustrate a proof-of-principle approach that can be used to obtain functionally informative mutants within a PPI network.

The B2H system as a tool to study circulating spike variants and their binding to ACE2

To further assess whether our B2H system can facilitate the study of emerging mutational changes in viral populations, we next asked whether we could use our system to study the interaction between the SARS-CoV-2 spike protein and ACE2. For this, we obtained an *E. coli* codon-optimized gene fragment encoding the human ACE2 peptidase domain (aa 19-615, hereafter ACE2). We inserted this gene fragment and a set of gene fragments encoding multiple domains of the spike protein (including the RBD, aa 331-521) into our two-hybrid vectors, fusing ACE2 and each of the spike domains to both λ CI and α NTD. Initial experiments using our standard *E. coli* B2H strain (FW102 OL2-62 termed B2H; Supplementary Table 1A) failed to reveal an interaction of ACE2 with any of the selected spike domains (Supplementary Fig. 7; data not shown). However, previous studies demonstrated that proper disulfide bond formation is essential in order for spike and ACE2 to engage in a direct interaction [34,35]. Because the *E. coli* cytoplasm is a reducing environment [36], we considered the possibility that the failure to detect a spike-ACE2 interaction with our standard B2H strain might be due to a lack of proper disulfide bond formation. To circumvent this obstacle, we modified a commercially available *E. coli* strain (SHuffle from NEB, MA, USA) that permits the efficient expression and formation of active full-length antibodies in the *E. coli* cytoplasm [37], adapting it for use with our two-hybrid system (Methods). The SHuffle strain is deleted for two genes that encode cytoplasmic reductases (*trxB* and *gor*) and also harbors the normally periplasmic disulfide bond isomerase DsbC in the cytoplasm [38,39]. With this modified oxidizing strain (termed BLS148; Supplementary Table 1A), we were able to detect an interaction of the spike RBD with ACE2 (Fig. 5A,B). Moreover, this interaction was abrogated when we mutated a pair of cysteine residues (replacing them individually and in combination with serine residues) that engage in

disulfide bond formation within the RBD (C379 and C432) [34], consistent with the surmise that the oxidizing strain permits detection of the RBD-ACE2 interaction by enabling appropriate disulfide bond formation and correct folding of the interacting partners (Fig. 5B; Supplementary Fig. 8).

Having adapted our B2H system for the study of disulfide bond-dependent PPIs, we sought to test different spike (RBD) circulating variants for their abilities to bind ACE2. The RBD amino acid substitutions included in our study are found in several SARS-CoV-2 variants that were previously designated VOCs by the Centers for Disease Control and Prevention (USA; <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html>, initially accessed 05/30/2021). Specifically, we included the Alpha variant (B.1.1.7, first identified in the United Kingdom) that carries the RBD N501Y substitution, the Beta variant (B.1.351, first identified in South Africa) that carries the RBD K417N, E484K and N501Y substitutions, as well as the Epsilon variant (B.1.429, first identified in California) that carries the RBD L452R substitution, introducing the corresponding mutations into the spike RBD on our B2H vector (Fig. 5D). The latter two variants have recently gained more attention as they are considered immune escape variants, potentially resulting in a partial loss of immunity in previously infected or immunized people [40–47]. In contrast, the Alpha variant is not characterized by a marked escape from antibody neutralization [41,42,45–47]. Factors that are believed to contribute, potentially, to immune escape include changes in the spike protein that: (i) enhance or stabilize its binding to ACE2 or (ii) decrease the binding of specific anti-spike neutralizing antibodies [48–50].

As well as testing the Alpha, Beta and Epsilon RBDs for their abilities to bind ACE2, we included RBD mutants bearing component single and double substitutions from the Beta variant (Fig. 5C; Supplementary Fig. 9). We found that the N501Y substitution (in the context of the Alpha variant) had no observable effect on ACE2 binding. In contrast, the L452R substitution (Epsilon variant) resulted in a statistically significant increase in ACE2 binding. Substitutions

K417N, E484K and N501Y (Beta variant) together resulted in a significant reduction in ACE2 binding, as did the individual component substitutions K417N and E484K (with the E484K substitution having the stronger effect). However, the effects of these two substitutions were partially (E484K) or fully (K417N) abrogated when combined with the N501Y substitution. The binding of the triply substituted variant was indistinguishable from that of the E484K/N501Y double mutant, indicating that in this context the K417N substitution neither weakens or strengthens the interaction. Together, these findings indicate that our modified B2H system enables detection of disulfide bond-dependent PPIs and can be used to investigate the effects of RBD variant substitutions on the RBD-ACE2 interaction.

Discussion

Use of bacteria-based assay to investigate SARS-CoV-2 interactome

Here we use a versatile bacteria-based genetic tool for detecting and dissecting PPIs [24,25] to screen the SARS-CoV-2 proteome for intraviral PPIs. We detected a total of sixteen PPIs, including four self-interactions. Nine of these interactions were also detected in a previous SARS-CoV-2 PPI study (Supplementary Fig. 3), as assessed by Y2H-based screens and/or mammalian cell-based co-IP experiments [6]. Additionally, four of the interactions we detected have been captured in co-crystal structures, including the Nsp9 self-interaction (PDB: 6W9Q; [32]), which was not identified by either Y2H or co-IP analyses [6]. Of the six interactions we detected that were not previously described in the context of SARS-CoV-2, three were previously detected by Y2H analyses in the context of SARS CoV-1 (Supplementary Fig. 4). Of the remaining three interactions, not previously described, two (Nsp9+Nsp11 and Nsp3+N) were particularly strong as assessed in our B2H assay (Fig. 3).

Although the different assays that have been used to characterize the SARS-CoV-2 interactome have provided results that often corroborate one another, there are many examples of interactions that have been detected with only one of the assays. These discrepancies highlight the importance of employing multiple assay systems, each with its own inherent limitations, to maximize the likelihood of obtaining a complete picture. Because of its experimental accessibility, we expect that our B2H assay will be useful in evaluating other viral proteomes, particularly by taking advantage of our oxidizing reporter strain that better approximates the eukaryotic cell environment in allowing for proper disulfide bond formation in the *E. coli* cytoplasm [51,52]. To further extend the spectrum of testable viral and eukaryotic PPIs, the system could be augmented to enable the detection of phosphorylation-dependent PPIs by introducing specific mammalian kinases into our reporter strain [53]. Given that many mammalian (and presumably viral) proteins are constitutively phosphorylated in yeast [54–56], a lack of properly phosphorylated proteins in our B2H system could explain, at least in principle, why some SARS-CoV-2 PPIs were identified only in the Y2H screens [6] and not in our system (Supplementary Fig. 3). We note, however, that a comprehensive phosphoproteomics analysis of SARS-CoV-2-infected cells [57] suggests that other than interactions involving the N protein, which was found to be phosphorylated at multiple sites, most of the viral PPIs that were detected by Y2H analysis but not in our B2H system involve proteins that were not detectably phosphorylated.

Genetic dissection of specific SARS-CoV-2 PPIs

A benefit of two-hybrid approaches for studying PPIs is that detected interactions can be readily dissected genetically, something that is particularly straightforward to do with our B2H system. As a proof-of-principle, we used a structure-based approach to investigate the effects of targeted mutations on specific SARS-CoV-2 PPIs, identifying substitutions that disrupt one interaction but not another. In addition to facilitating the evaluation of specific circulating or

targeted mutations, our B2H system can readily be adapted to screen for randomly generated mutations that selectively affect one PPI and not another [58] when there is insufficient information to make informed predictions from structural or other data. The identification of such mutations could facilitate the functional analysis of particular PPIs and inform the choice of potential drug targets for small molecule drug design. Furthermore, with a suitably modified reporter strain to improve compound accessibility [59], compound or peptide libraries could be screened to identify candidates that might target specific SARS-CoV-2 PPIs. It should also be feasible to adapt our B2H reporter system for an *in vitro* cell-free protein expression system, thereby facilitating compound screenings.

Use of oxidizing B2H reporter strain enables detection of RBD-ACE2 interaction

Based on previous studies, we anticipated a high-affinity interaction between the spike RBD and ACE2 [9,23,34]. With our modified bacteria-based system, we found that the RBD-ACE2 interaction resulted in a roughly 3-fold increase in *lacZ* reporter gene expression over background, a relatively modest effect. One possible explanation is that the λ CI-ACE2 fusion protein is produced at relatively low levels compared with unfused λ CI and other λ CI fusion proteins we have studied in the past (Supplementary Fig. 8), perhaps resulting in intracellular concentrations insufficient to saturate the DNA-binding site on our *lacZ* reporter. Another possible explanation (not mutually exclusive) lies in the fact that both the SARS-CoV-2 spike protein and ACE2 are glycosylated in mammalian cells [9,60], with some studies suggesting that glycan-side chain interactions may be important in stabilizing the RBD-ACE2 interaction [61,62]. Thus, the interaction detected in our B2H system could be compromised by the lack of mammalian-like N- and O-glycosylation in *E. coli* [63].

Our B2H system enabled us to assess the effects of specific RBD amino acid substitutions that have been identified in globally circulating SARS-CoV-2 variants. We focused

specifically on three VOCs, as designated by the CDC at the time we initiated our study: the Alpha variant (B.1.1.7), the Beta variant (B.1.351) and the Epsilon variant (B.1.429), carrying RBD substitutions N501Y, N501Y/K417N/E484K, and L452R, respectively (see Fig. 5D) [41]. We note that as of September 21, 2021 each of these variants has been deescalated from a VOC to a variant being monitored (VBM) by the CDC. We also note that the highly contagious and rapidly proliferating Delta variant, currently designated as a VOC, harbors the L452R substitution in the RBD, together with a second substitution (T478K) [64].

Mutated in both the Alpha and the Beta variants, residue N501 is localized at the binding interface with ACE2 [34,65] and many reports have suggested that the N501Y substitution increases the affinity of the RBD for ACE2 [23,48,66–70] (but see [71] for a discrepant prediction), potentially explaining the elevated infectivity of the Alpha variant. In a study in which the effects of all possible RBD amino acid substitutions were examined using a yeast-surface-display platform, Starr *et al.* identified N501Y as one of the substitutions causing the highest gain in ACE2-binding affinity [23]. In contrast, our B2H assay did not reveal any significant effect of the N501Y substitution on the strength of the RBD-ACE2 interaction. Possibly this discrepancy is due to the lack of glycosylation in the bacterial system; in fact, an ACE2 glycan (N322) that has been reported to enhance RBD-ACE2 binding is part of the same binding patch that includes N501 [62]. Nonetheless, we did observe a binding enhancing, compensatory effect of the N501Y substitution when tested in the context of the Beta variant. That is, we found that Beta-associated substitutions K417N and E484K both reduced ACE2 binding when tested individually, and that the N501Y substitution compensated for these effects, partially in the case of E484K and fully in the case of K417N. Our results thus suggest that substitutions K417N and E484K, which have been implicated in significant immune escape [43–45,72–74], may impose a cost on ACE2 binding that is compensated by the N501Y substitution (see also [70]). Consistent with our findings, the K417N substitution has been previously reported to weaken ACE2 binding

[72,75,76]; however, in contrast with our results, Starr *et al.* [23] found that the E484K substitution had a small positive effect on ACE2 binding.

In the case of the L452R substitution, which is present in the Epsilon variant and also in the Delta variant [64], we observed a modest enhancement of ACE2 binding. Residue L452 is positioned at the edge of the binding interface with ACE2 and although this residue does not make direct contact with ACE2 [34,77], evidence suggests that substitution L452R enhances viral infectivity significantly [77,78]. Furthermore, it has been suggested that the L452R mutation is responsible for the dramatic clonal expansion of lineages carrying this mutation [79], possibly due to a decrease in the potency of antibody neutralization or through other immune escape characteristics [44,46,64,77,78,80]. Whether or not an effect of the L452R substitution on ACE2 binding, apparently modest, is a contributing factor in the rapid spread of variants carrying this mutation remains to be determined.

Summary

Taken together, our results illustrate the utility of a B2H system as an accessible and economical genetic tool to complement other methods for studying viral PPIs. To the best of our knowledge, we provide the first bacteria-based viral interactome, describing sixteen different intraviral PPIs from SARS-CoV-2. As a non-eukaryotic system, the B2H assay is unlikely to contain bridging factors that can complicate the interpretation of positive results. At the same time, the bacterial system lacks the machinery for enabling potentially relevant post-translational modifications such as protein phosphorylation (which could however be engineered into the system; [53]) and protein glycosylation. Although generally a limitation, the lack of protein glycosylation could in certain situations be informative, enabling a comparison between systems that do and do not support this modification. The new oxidizing B2H reporter strain that we describe enabled us to detect the SARS-CoV-2 spike RBD-ACE2 interaction and characterize

389 the effects of several RBD substitutions present in circulating variants. This strain provides a
390 means to test newly arising coronavirus lineages for binding to ACE2 or other human cell
391 surface receptors in the future, as well as extending the reach of the B2H system to include
392 disulfide bond-dependent PPIs in general.

References

- 1 Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang R Di, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF & Shi ZL (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270–273.
- 2 Hu B, Guo H, Zhou P & Shi ZL (2021) Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol* **19**, 141–154.
- 3 V'kovski P, Kratzel A, Steiner S, Stalder H & Thiel V (2021) Coronavirus biology and replication: implications for SARS-CoV-2. *Nat Rev Microbiol* **19**, 155–170.
- 4 Park A & Iwasaki A (2020) Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19. *Cell Host Microbe* **27**, 870–878.
- 5 Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, Yuan ML, Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC & Zhang YZ (2020) A new coronavirus associated with human respiratory disease in China. *Nature* **579**, 265–269.
- 6 Li J, Guo M, Tian X, Wang X, Yang X, Wu P, Liu C, Xiao Z, Qu Y, Yin Y, Wang C, Zhang Y, Zhu Z, Liu Z, Peng C, Zhu T & Liang Q (2021) Virus-Host Interactome and Proteomic Survey Reveal Potential Virulence Factors Influencing SARS-CoV-2 Pathogenesis. *Med* **2**, 99-112.e7.
- 7 von Brunn A, Teepe C, Simpson JC, Pepperkok R, Friedel CC, Zimmer R, Roberts R, Baric R & Haas J (2007) Analysis of intraviral protein-protein interactions of the SARS coronavirus ORFeome. *PLoS One* **2**, e459.
- 8 Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS & McLellan JS (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* **367**, 1260–1263.
- 9 Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT & Veesler D (2020) Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* **181**, 281-292.e6.
- 10 Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C & Pöhlmann S (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280.e8.
- 11 Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann AJ, Cornaby C, Bartelt L, Weiss S, Park Y, Edwards CE, Weimer E, Scherer EM, Rouphael N, Edupuganti S, Weiskopf D, Tse L V., Hou YJ, Margolis D, Sette A, Collins MH, Schmitz J, Baric RS & de Silva AM (2020) The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Sci Immunol* **5**, 1–15.
- 12 Barnes CO, Jette CA, Abernathy ME, Dam K-MA, Esswein SR, Gristick HB, Malyutin AG, Sharaf NG, Huey-Tubman KE, Lee YE, Robbiani DF, Nussenzweig MC, West AP &

- 433 Bjorkman PJ (2020) SARS-CoV-2 neutralizing antibody structures inform therapeutic
434 strategies. *Nature* **588**, 682–687.
- 435 13 Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JFW, Sahi V, Figueroa A, Guo
436 X V., Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KY, Kwong PD, Sodroski JG,
437 Yin MT, Sheng Z, Huang Y, Shapiro L & Ho DD (2020) Potent neutralizing antibodies
438 against multiple epitopes on SARS-CoV-2 spike. *Nature* **584**, 450–456.
- 439 14 Barnes CO, West AP, Huey-Tubman KE, Hoffmann MAG, Sharaf NG, Hoffman PR, Koranda
440 N, Gristick HB, Gaebler C, Muecksch F, Cetrulo Lorenzi JC, Finkin S, Hägglöf T, Hurley A,
441 Millard KG, Weisblum Y, Schmidt F, Hatzioannou T, Bieniasz PD, Caskey M, Robbiani DF,
442 Nussenzweig MC & Bjorkman PJ (2020) Structures of human antibodies bound to SARS-
443 CoV-2 spike reveal common epitopes and recurrent features of antibodies. *Cell* **182**, 828-
444 842.e16.
- 445 15 Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, Jaconi S, Culap K, Zatta
446 F, De Marco A, Peter A, Guarino B, Spreafico R, Cameroni E, Case JB, Chen RE,
447 Havenar-Daughton C, Snell G, Telenti A, Virgin HW, Lanzavecchia A, Diamond MS, Fink
448 K, Veesler D & Corti D (2020) Cross-neutralization of SARS-CoV-2 by a human
449 monoclonal SARS-CoV antibody. *Nature* **583**, 290–295.
- 450 16 Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, Agudelo M, Barnes
451 CO, Gazumyan A, Finkin S, Hägglöf T, Oliveira TY, Viant C, Hurley A, Hoffmann HH,
452 Millard KG, Kost RG, Cipolla M, Gordon K, Bianchini F, Chen ST, Ramos V, Patel R, Dizon
453 J, Shimeliovich I, Mendoza P, Hartweg H, Nogueira L, Pack M, Horowitz J, Schmidt F,
454 Weisblum Y, Michailidis E, Ashbrook AW, Waltari E, Pak JE, Huey-Tubman KE, Koranda
455 N, Hoffman PR, West AP, Rice CM, Hatzioannou T, Bjorkman PJ, Bieniasz PD, Caskey M
456 & Nussenzweig MC (2020) Convergent antibody responses to SARS-CoV-2 in
457 convalescent individuals. *Nature* **584**, 437–442.
- 458 17 Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, Schäfer A, Reidy JX,
459 Trivette A, Nargi RS, Sutton RE, Suryadevara N, Martinez DR, Williamson LE, Chen EC,
460 Jones T, Day S, Myers L, Hassan AO, Kafai NM, Winkler ES, Fox JM, Shrihari S, Mueller
461 BK, Meiler J, Chandrashekar A, Mercado NB, Steinhardt JJ, Ren K, Loo Y-M, Kallewaard
462 NL, McCune BT, Keeler SP, Holtzman MJ, Barouch DH, Gralinski LE, Baric RS, Thackray
463 LB, Diamond MS, Carnahan RH & Crowe JE (2020) Potently neutralizing and protective
464 human antibodies against SARS-CoV-2. *Nature* **584**, 443–449.
- 465 18 Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He W, Limbo O, Smith C, Song G, Woehl
466 J, Yang L, Abbott RK, Callaghan S, Garcia E, Hurtado J, Parren M, Peng L, Ramirez S,
467 Ricketts J, Ricciardi MJ, Rawlings SA, Wu NC, Yuan M, Smith DM, Nemazee D, Teijaro
468 JR, Voss JE, Wilson IA, Andrabi R, Briney B, Landais E, Sok D, Jardine JG & Burton DR
469 (2020) Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease
470 in a small animal model. *Science* **369**, 956–963.
- 471 19 van Dorp L, Acman M, Richard D, Shaw LP, Ford CE, Ormond L, Owen CJ, Pang J, Tan
472 CCS, Boshier FAT, Ortiz AT & Balloux F (2020) Emergence of genomic diversity and
473 recurrent mutations in SARS-CoV-2. *Infect Genet Evol* **83**, 104351.
- 474 20 Singh D & Yi S V (2021) On the origin and evolution of SARS-CoV-2. *Exp Mol Med* **53**, 537–
475 547.
- 476 21 van Dorp L, Richard D, Tan CCS, Shaw LP, Acman M & Balloux F (2020) No evidence for

- 477 increased transmissibility from recurrent mutations in SARS-CoV-2. *Nat Commun* **11**,
478 5986.
- 479 22 De Maio N, Walker CR, Turakhia Y, Lanfear R, Corbett-Detig R & Goldman N (2021)
480 Mutation Rates and Selection on Synonymous Mutations in SARS-CoV-2. *Genome Biol*
481 *Evol* **13**, 1–14.
- 482 23 Starr TN, Greaney AJ, Hilton SK, Ellis D, Crawford KHD, Dingens AS, Navarro MJ, Bowen
483 JE, Tortorici MA, Walls AC, King NP, Veessler D & Bloom JD (2020) Deep Mutational
484 Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and
485 ACE2 Binding. *Cell* **182**, 1295-1310.e20.
- 486 24 Dove SL & Hochschild A (2004) A Bacterial Two-Hybrid System Based on Transcription
487 Activation. In *Protein-Protein Interactions. Methods and Applications* (Fu H, ed), pp. 231–
488 246. Humana Press, Totowa, NJ.
- 489 25 Dove SL, Joung JK & Hochschild A (1997) Activation of prokaryotic transcription through
490 arbitrary protein–protein contacts. *Nature* **386**, 627–630.
- 491 26 Pan J, Peng X, Gao Y, Li Z, Lu X, Chen Y, Ishaq M, Liu D, DeDiego ML, Enjuanes L & Guo
492 D (2008) Genome-wide analysis of protein-protein interactions and involvement of viral
493 proteins in SARS-CoV replication. *PLoS One* **3**, e3299.
- 494 27 Imbert I, Snijder EJ, Dimitrova M, Guillemot JC, Lécine P & Canard B (2008) The SARS-
495 Coronavirus PLnc domain of nsp3 as a replication/transcription scaffolding protein. *Virus*
496 *Res* **133**, 136–148.
- 497 28 Konkolova E, Klima M, Nencka R & Boura E (2020) Structural analysis of the putative SARS-
498 CoV-2 primase complex. *J Struct Biol* **211**, 107548.
- 499 29 Ferron F, Subissi L, Silveira De Moraes AT, Le NTT, Sevajol M, Gluais L, Decroly E,
500 Vonnrhein C, Bricogne G, Canard B & Imbert I (2018) Structural and molecular basis of
501 mismatch correction and ribavirin excision from coronavirus RNA. *Proc Natl Acad Sci* **115**,
502 E162–E171.
- 503 30 Lin S, Chen H, Chen Z, Yang F, Ye F, Zheng Y, Yang J, Lin X, Sun H, Wang L, Wen A,
504 Dong H, Xiao Q, Deng D, Cao Y & Lu G (2021) Crystal structure of SARS-CoV-2 nsp10
505 bound to nsp14-ExoN domain reveals an exoribonuclease with both structural and
506 functional integrity. *Nucleic Acids Res* **49**, 5382–5392.
- 507 31 Rosas-Lemus M, Minasov G, Shuvalova L, Inniss NL, Kiryukhina O, Brunzelle J & Satchell
508 KJF (2020) High-resolution structures of the SARS-CoV-2 2'-O-methyltransferase reveal
509 strategies for structure-based inhibitor design. *Sci Signal* **13**, eabe1202.
- 510 32 Littler DR, Gully BS, Colson RN & Rossjohn J (2020) Crystal structure of the SARS-CoV-2
511 non-structural protein 9, Nsp9. *iScience* **23**, 101258.
- 512 33 Krissinel E & Henrick K (2007) Inference of Macromolecular Assemblies from Crystalline
513 State. *J Mol Biol* **372**, 774–797.
- 514 34 Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L & Wang X
515 (2020) Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2
516 receptor. *Nature* **581**, 215–220.

- 517 35 Hati S & Bhattacharyya S (2020) Impact of Thiol-Disulfide Balance on the Binding of Covid-
518 19 Spike Protein with Angiotensin-Converting Enzyme 2 Receptor. *ACS Omega* **5**, 16292–
519 16298.
- 520 36 Stewart EJ, Åslund F & Beckwith J (1998) Disulfide bond formation in the Escherichia coli
521 cytoplasm: An in vivo role reversal for the thioredoxins. *EMBO J* **17**, 5543–5550.
- 522 37 Robinson MP, Ke N, Lobstein J, Peterson C, Szkodny A, Mansell TJ, Tuckey C, Riggs PD,
523 Colussi PA, Noren CJ, Taron CH, Delisa MP & Berkmen M (2015) Efficient expression of
524 full-length antibodies in the cytoplasm of engineered bacteria. *Nat Commun* **6**, 8072.
- 525 38 Bessette PH, Åslund F, Beckwith J & Georgiou G (1999) Efficient folding of proteins with
526 multiple disulfide bonds in the Escherichia coli cytoplasm. *Proc Natl Acad Sci U S A* **96**,
527 13703–13708.
- 528 39 Lobstein J, Emrich CA, Jeans C, Faulkner M, Riggs P & Berkmen M (2012) SHuffle, a novel
529 Escherichia coli protein expression strain capable of correctly folding disulfide bonded
530 proteins in its cytoplasm. *Microb Cell Fact* **11**, 753.
- 531 40 Stamatatos L, Czartoski J, Wan Y-H, Homad LJ, Rubin V, Glantz H, Neradilek M, Seydoux
532 E, Jennewein MF, MacCamy AJ, Feng J, Mize G, De Rosa SC, Finzi A, Lemos MP, Cohen
533 KW, Moodie Z, McElrath MJ & McGuire AT (2021) mRNA vaccination boosts cross-variant
534 neutralizing antibodies elicited by SARS-CoV-2 infection. *Science* **372**, 1413–1418.
- 535 41 Starr TN, Greaney AJ, Dingens AS & Bloom JD (2021) Complete map of SARS-CoV-2 RBD
536 mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-
537 CoV016. *Cell Reports Med* **2**, 100255.
- 538 42 Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F, Planchais C,
539 Buchrieser J, Rajah MM, Bishop E, Albert M, Donati F, Prot M, Behillil S, Enouf V, Maquart
540 M, Smati-Lafarge M, Varon E, Schortgen F, Yahyaoui L, Gonzalez M, De Sèze J, Péré H,
541 Veyer D, Sève A, Simon-Lorière E, Fafi-Kremer S, Stefic K, Mouquet H, Hocqueloux L, van
542 der Werf S, Prazuck T & Schwartz O (2021) Sensitivity of infectious SARS-CoV-2 B.1.1.7
543 and B.1.351 variants to neutralizing antibodies. *Nat Med* **27**, 917–924.
- 544 43 Liu Z, VanBlargan LA, Bloyet LM, Rothlauf PW, Chen RE, Stumpf S, Zhao H, Errico JM,
545 Theel ES, Liebeskind MJ, Alford B, Buchser WJ, Ellebedy AH, Fremont DH, Diamond MS
546 & Whelan SPJ (2021) Identification of SARS-CoV-2 spike mutations that attenuate
547 monoclonal and serum antibody neutralization. *Cell Host Microbe* **29**, 477-488.e4.
- 548 44 Greaney AJ, Starr TN, Barnes CO, Weisblum Y, Schmidt F, Caskey M, Gaebler C, Cho A,
549 Agudelo M, Finkin S, Wang Z, Poston D, Muecksch F, Hatzioannou T, Bieniasz PD,
550 Robbiani DF, Nussenzweig MC, Bjorkman PJ & Bloom JD (2021) Mapping mutations to the
551 SARS-CoV-2 RBD that escape binding by different classes of antibodies. *Nat Commun* **12**,
552 4196.
- 553 45 Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD,
554 Graham BS, Mascola JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L,
555 Sheng Z, Huang Y & Ho DD (2021) Antibody resistance of SARS-CoV-2 variants B.1.351
556 and B.1.1.7. *Nature* **593**, 130–135.
- 557 46 McCallum M, Bassi J, Marco A De, Chen A, Walls AC, Iulio J Di, Tortorici MA, Navarro M-J,
558 Silacci-Fregni C, Saliba C, Agostini M, Pinto D, Culap K, Bianchi S, Jaconi S, Cameroni E,

559 Bowen JE, Tilles SW, Pizzuto MS, Guastalla SB, Bona G, Pellanda AF, Garzoni C, Van
560 Voorhis WC, Rosen LE, Snell G, Telenti A, Virgin HW, Piccoli L, Corti D & Veessler D
561 (2021) SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. *Science* **373**, 648–654.

562 47 Garcia-Beltran WF, Lam EC, St. Denis K, Nitido AD, Garcia ZH, Hauser BM, Feldman J,
563 Pavlovic MN, Gregory DJ, Poznansky MC, Sigal A, Schmidt AG, Iafrate AJ, Naranbhai V &
564 Balazs AB (2021) Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced
565 humoral immunity. *Cell* **184**, 2372-2383.e9.

566 48 Clark SA, Clark LE, Pan J, Coscia A, McKay LGA, Shankar S, Johnson RI, Brusic V,
567 Choudhary MC, Regan J, Li JZ, Griffiths A & Abraham J (2021) SARS-CoV-2 evolution in
568 an immunocompromised host reveals shared neutralization escape mechanisms. *Cell* **184**,
569 2605-2617.e18.

570 49 Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, Solomon IH, Kuo H-H,
571 Boucau J, Bowman K, Adhikari U Das, Winkler ML, Mueller AA, Hsu TY-T, Desjardins M,
572 Baden LR, Chan BT, Walker BD, Lichterfeld M, Brigl M, Kwon DS, Kanjilal S, Richardson
573 ET, Jonsson AH, Alter G, Barczak AK, Hanage WP, Yu XG, Gaiha GD, Seaman MS,
574 Cernadas M & Li JZ (2020) Persistence and Evolution of SARS-CoV-2 in an
575 Immunocompromised Host. *N Engl J Med* **383**, 2291–2293.

576 50 Starr TN, Greaney AJ, Addetia A, Hannon WW, Choudhary MC, Dingens AS, Li JZ & Bloom
577 JD (2021) Prospective mapping of viral mutations that escape antibodies used to treat
578 COVID-19. *Science* **371**, 850–854.

579 51 Berkmen M (2012) Production of disulfide-bonded proteins in *Escherichia coli*. *Protein Expr*
580 *Purif* **82**, 240–251.

581 52 Ren G, Ke N & Berkmen M (2016) Use of the SHuffle strains in production of proteins. *Curr*
582 *Protoc Protein Sci* **2016**, 5.26.1-5.26.21.

583 53 Shaywitz AJ, Dove SL, Kornhauser JM, Hochschild A & Greenberg ME (2000) Magnitude of
584 the CREB-Dependent Transcriptional Response Is Determined by the Strength of the
585 Interaction between the Kinase-Inducible Domain of CREB and the KIX Domain of CREB-
586 Binding Protein. *Mol Cell Biol* **20**, 9409–9422.

587 54 Ptacek J, Devgan G, Michaud G, Zhu H, Zhu X, Fasolo J, Guo H, Jona G, Breitkreutz A,
588 Sopko R, McCartney RR, Schmidt MC, Rachidi N, Lee SJ, Mah AS, Meng L, Stark MJR,
589 Stern DF, De Virgilio C, Tyers M, Andrews B, Gerstein M, Schweitzer B, Predki PF &
590 Snyder M (2005) Global analysis of protein phosphorylation in yeast. *Nature* **438**, 679–684.

591 55 Errede B & Levin DE (1993) A conserved kinase cascade for MAP kinase activation in yeast.
592 *Curr Opin Cell Biol* **5**, 254–260.

593 56 Hanks SK, Quinn AM & Hunter T (1988) The protein kinase family: conserved features and
594 deduced phylogeny of the catalytic domains. *Science* **241**, 42–52.

595 57 Bouhaddou M, Memon D, Meyer B, White KM, Rezeli V V., Correa Marrero M, Polacco BJ,
596 Melnyk JE, Ulferts S, Kaake RM, Batra J, Richards AL, Stevenson E, Gordon DE, Rojc A,
597 Obernier K, Fabius JM, Soucheray M, Miorin L, Moreno E, Koh C, Tran QD, Hardy A,
598 Robinot R, Vallet T, Nilsson-Payant BE, Hernandez-Armenta C, Dunham A, Weigang S,
599 Knerr J, Modak M, Quintero D, Zhou Y, Dugourd A, Valdeolivas A, Patil T, Li Q, Hüttenhain
600 R, Cakir M, Muralidharan M, Kim M, Jang G, Tutuncuoglu B, Hiatt J, Guo JZ, Xu J,

- 601 Bouhaddou S, Mathy CJP, Gaulton A, Manners EJ, Félix E, Shi Y, Goff M, Lim JK, McBride
602 T, O'Neal MC, Cai Y, Chang JCJ, Broadhurst DJ, Klippsten S, De wit E, Leach AR,
603 Kortemme T, Shoichet B, Ott M, Saez-Rodriguez J, tenOever BR, Mullins RD, Fischer ER,
604 Kochs G, Grosse R, García-Sastre A, Vignuzzi M, Johnson JR, Shokat KM, Swaney DL,
605 Beltrao P & Krogan NJ (2020) The Global Phosphorylation Landscape of SARS-CoV-2
606 Infection. *Cell* **182**, 685-712.e19.
- 607 58 Heller DM, Tavag M & Hochschild A (2017) *CbtA toxin of Escherichia coli inhibits cell division*
608 *and cell elongation via direct and independent interactions with FtsZ and MreB*. *PLoS Gen*
609 **13**, 1-38.
- 610 59 Althoff EA & Cornish VW (2002) A Bacterial Small-Molecule Three-Hybrid System. *Angew*
611 *Chemie Int Ed* **41**, 2327-2330.
- 612 60 Zhao P, Praissman JL, Grant OC, Cai Y, Xiao T, Rosenbalm KE, Aoki K, Kellman BP,
613 Bridger R, Barouch DH, Brindley MA, Lewis NE, Tiemeyer M, Chen B, Woods RJ & Wells L
614 (2020) Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2
615 Receptor. *Cell Host Microbe* **28**, 586-601.e6.
- 616 61 Acharya A, Lynch DL, Pavlova A, Pang YT & Gumbart JC (2021) ACE2 glycans
617 preferentially interact with SARS-CoV-2 over SARS-CoV. *Chem Commun* **57**, 5949-5952.
- 618 62 Mehdipour AR & Hummer G (2021) Dual nature of human ACE2 glycosylation in binding to
619 SARS-CoV-2 spike. *Proc Natl Acad Sci U S A* **118**, e2100425118.
- 620 63 Du T, Buenbrazo N, Kell L, Rahmani S, Sim L, Withers SG, DeFrees S & Wakarchuk W
621 (2019) A Bacterial Expression Platform for Production of Therapeutic Proteins Containing
622 Human-like O-Linked Glycans. *Cell Chem Biol* **26**, 203-212.e5.
- 623 64 Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C,
624 Porrot F, Robillard N, Puech J, Prot M, Gallais F, Gantner P, Velay A, Le Guen J, Kassis-
625 Chikhani N, Edriss D, Belec L, Seve A, Courtellemont L, Péré H, Hocqueloux L, Fafi-
626 Kremer S, Prazuck T, Mouquet H, Bruel T, Simon-Lorière E, Rey FA & Schwartz O (2021)
627 Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature* **596**,
628 276-280.
- 629 65 Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A & Li F (2020) Structural
630 basis of receptor recognition by SARS-CoV-2. *Nature* **581**, 221-224.
- 631 66 Luan B, Wang H & Huynh T (2021) Enhanced binding of the N501Y-mutated SARS-CoV-2
632 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations.
633 *FEBS Lett* **595**, 1454-1461.
- 634 67 Chan CEZ, Seah SGK, Chye DH, Massey S, Torres M, Lim APC, Wong SKK, Neo JJY,
635 Wong PS, Lim JH, Loh GSL, Wang D, Boyd-Kirkup JD, Guan S, Thakkar D, Teo GH,
636 Purushotorman K, Hutchinson PE, Young BE, Low JG, MacAry PA, Hentze H,
637 Prativadibhayankara VS, Ethirajulu K, Comer JE, Tseng C-TK, Barrett ADT, Ingram PJ,
638 Brasel T & Hanson BJ (2021) The Fc-mediated effector functions of a potent SARS-CoV-2
639 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are
640 essential for the optimal therapeutic efficacy of the antibody. *PLoS One* **16**, e0253487.
- 641 68 Ramanathan M, Ferguson ID, Miao W & Khavari PA (2021) SARS-CoV-2 B.1.1.7 and
642 B.1.351 spike variants bind human ACE2 with increased affinity. *Lancet Infect Dis* **21**,

643 1070.

644 69 Ali F, Kasry A & Amin M (2021) The new SARS-CoV-2 strain shows a stronger binding
645 affinity to ACE2 due to N501Y mutant. *Med Drug Discov* **10**, 100086.

646 70 Villoutreix BO, Calvez V, Marcelin AG & Khatib AM (2021) In silico investigation of the new
647 UK (B.1.1.7) and South African (501y.v2) SARS-CoV-2 variants with a focus at the ace2–
648 spike rbd interface. *Int J Mol Sci* **22**, 1–13.

649 71 Socher E, Conrad M, Heger L, Paulsen F, Sticht H, Zunke F & Arnold P (2021) Mutations in
650 the B.1.1.7 SARS-CoV-2 Spike Protein Reduce Receptor-Binding Affinity and Induce a
651 Flexible Link to the Fusion Peptide. *Biomedicines* **9**, 525.

652 72 Huang SW & Wang SF (2021) SARS-CoV-2 entry related viral and host genetic variations:
653 Implications on covid-19 severity, immune escape, and infectivity. *Int J Mol Sci* **22**, 1–22.

654 73 Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY & Bloom JD (2021)
655 Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that
656 affect recognition by polyclonal human plasma antibodies. *Cell Host Microbe* **29**, 463-
657 476.e6.

658 74 Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, Hilton SK, Huddleston J,
659 Eguia R, Crawford KHD, Dingens AS, Nargi RS, Sutton RE, Suryadevara N, Rothlauf PW,
660 Liu Z, Whelan SPJ, Carnahan RH, Crowe JE & Bloom JD (2021) Complete Mapping of
661 Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody
662 Recognition. *Cell Host Microbe* **29**, 44-57.e9.

663 75 Laffebber C, de Koning K, Kanaar R & Lebbink JHG (2021) Experimental Evidence for
664 Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants. *J Mol Biol* **433**,
665 167058.

666 76 Yi C, Sun X, Ye J, Ding L, Liu M, Yang Z, Lu X, Zhang Y, Ma L, Gu W, Qu A, Xu J, Shi Z,
667 Ling Z & Sun B (2020) Key residues of the receptor binding motif in the spike protein of
668 SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. *Cell Mol Immunol* **17**,
669 621–630.

670 77 Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, Sotomayor-
671 González A, Glasner DR, Reyes KR, Gliwa AS, Reddy NP, Sanchez San Martin C,
672 Federman S, Cheng J, Balcersek J, Taylor J, Streithorst JA, Miller S, Sreekumar B, Chen P-
673 Y, Schulze-Gahmen U, Taha TY, Hayashi JM, Simoneau CR, Kumar GR, McMahon S,
674 Lidsky P V, Xiao Y, Hemarajata P, Green NM, Espinosa A, Kath C, Haw M, Bell J, Hacker
675 JK, Hanson C, Wadford DA, Anaya C, Ferguson D, Frankino PA, Shivram H, Lareau LF,
676 Wyman SK, Ott M, Andino R & Chiu CY (2021) Transmission, infectivity, and neutralization
677 of a spike L452R SARS-CoV-2 variant. *Cell* **184**, 3426-3437.e8.

678 78 Motozono C, Toyoda M, Zahradnik J, Saito A, Nasser H, Tan TS, Ngare I, Kimura I, Uriu K,
679 Kosugi Y, Yue Y, Shimizu R, Ito J, Torii S, Yonekawa A, Shimono N, Nagasaki Y, Minami
680 R, Toya T, Sekiya N, Fukuhara T, Matsuura Y, Schreiber G, Ikeda T, Nakagawa S, Ueno T
681 & Sato K (2021) SARS-CoV-2 spike L452R variant evades cellular immunity and increases
682 infectivity. *Cell Host Microbe* **29**, 1124-1136.e11.

683 79 Tchesnokova V, Kulakesara H, Larson L, Bowers V, Rechkina E, Kisiela D, Sledneva Y,
684 Choudhury D, Maslova I, Deng K, Kutumbaka K, Geng H, Fowler C, Greene D, Ralston J,

685 Samadpour M & Sokurenko E (2021) Acquisition of the L452R mutation in the ACE2-
686 binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2
687 variants. *J Clin Microbiol*, doi:10.1128/JCM.00921-21.

688 80 Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, Zhao C, Zhang Q, Liu H, Nie L, Qin H, Wang M, Lu
689 Q, Li X, Sun Q, Liu J, Zhang L, Li X, Huang W & Wang Y (2020) The Impact of Mutations in
690 SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. *Cell* **182**, 1284-1294.e9.

691 81 Kuznedelov K, Minakhin L, Niedziela-Majka A, Dove SL, Rogulja D, Nickels BE, Hochschild
692 A, Heyduk T & Severinov K (2002) A role for interaction of the RNA polymerase flap
693 domain with the σ subunit in promoter recognition. *Science* **295**, 855–857.

694 82 Deighan P, Diez CM, Leibman M, Hochschild A & Nickels BE (2008) The bacteriophage λ Q
695 antiterminator protein contacts the β -flap domain of RNA polymerase. *Proc Natl Acad Sci*
696 **105**, 15305–15310.

697 83 Chung CT, Niemela SL & Miller RH (1989) One-step preparation of competent *Escherichia*
698 *coli*: transformation and storage of bacterial cells in the same solution. *Proc Natl Acad Sci*
699 **86**, 2172–2175.

700 84 Deaconescu AM, Chambers AL, Smith AJ, Nickels BE, Hochschild A, Savery NJ & Darst SA
701 (2006) Structural Basis for Bacterial Transcription-Coupled DNA Repair. *Cell* **124**, 507–
702 520.

703 85 Thibodeau SA, Fang R & Joung JK (2004) High-throughput β -galactosidase assay for
704 bacterial cell-based reporter systems. *Biotechniques* **36**, 410–415.

705

Figure Legends

Fig. 1: Bacterial two-hybrid assay used to study the SARS-CoV-2 interactome. (A) (top) Schematic depiction of the employed transcription-based bacterial two-hybrid system. Interaction between protein moieties X (purple) and Y (slate blue), which are fused to the N-terminal domain of the α subunit of *E. coli* RNAP (α NTD) and the λ CI protein, respectively, stabilizes the binding of RNAP to test promoter p_{lacO_L2-62} , thereby activating transcription of the *lacZ* reporter gene. The test promoter bears the λ operator O_L2 centered at position -62 upstream of the transcription start site. (bottom) *E. coli* cell containing genetic elements that are involved in the bacterial two-hybrid system. The chromosomal *lacZ* locus is deleted and the test promoter and fused *lacZ* reporter gene are encoded on an F' episome. The λ CI-Y and α NTD-X fusion proteins are encoded on compatible plasmids and produced under the control of IPTG-inducible promoters. (B) List of all tested SARS-CoV-2 ORFs as predicted by the NCBI reference genome (Accession #: NC_045512.2). The respective nucleotide range for each ORF based on the NCBI reference sequence is indicated, together with the resulting amino acid sequence length. Except for the spike protein, all ORFs were cloned as full-length genes. For spike, we chose to test the interaction of its ectodomain (aa 16-1213) to avoid complications due to its N-terminal signal peptide and C-terminal transmembrane domain.

Fig. 2: Detection of protein-protein interactions by the bacterial two-hybrid system. Interaction matrix of all tested ORFs. Positive interactions, regardless of the fusion partner, are indicated with purple squares and self-interactions are indicated by orange-framed squares. Detailed information about fusion constructs for which positive interactions were identified is given in Supplementary Fig. 1. To avoid data duplication, only one half of the matrix is shown while the other is shaded in grey.

Fig. 3: Strong SARS-CoV-2 protein-protein interactions identified by B2H assays. Shown are two-hybrid data for strong interactions (arbitrarily defined as Miller units > 500). Indicated ORFs are fused either to the α NTD (indicated as α) or to full-length λ CI (indicated as CI). α and λ CI negative controls express full-length α and full-length λ CI, respectively. The interaction of domain 4 of the RNAP σ^{70} subunit (fused to the α NTD) with the flap domain of the RNAP β subunit (fused to λ CI) served as a positive control (pos) [81,82]. Bar graphs show the averages of three biological replicates (n=3) and β -galactosidase activities are given in Miller units. Error bars indicate the standard deviation. Values indicated with asterisks are significantly different from the negative control. ****: $P < 0.0001$ (One-way ANOVA with Turkey's multiple comparison test).

Fig. 4: Selective disruption of protein interfaces for protein with two interaction partners. (A) Depiction of crystal structure (PDB ID: 5NFY [29]) of SARS-CoV-1 Nsp10 (pale cyan) in complex with Nsp14 (pale pink). Zoom-in shows amino acids (sticks) chosen for mutational analysis of Nsp10 (orange, olive, and burgundy) and their corresponding main interaction partners in Nsp14 (pale pink). (B) B2H results showing effects of Nsp10 substitutions on its interactions with Nsp14 and with Nsp16. Amino acid substitutions introduced into Nsp10 are given in the box. (C) Depiction of crystal structure of the SARS-CoV-2 Nsp16-Nsp10 protein complex (PDB ID: 6W4H [31]) colored respectively in pale yellow and pale cyan. Additional N-terminal Nsp10⁷⁻²² region is included and was obtained from superimposed Nsp10 structure from PDB ID: 5NFY (green). Zoom-in shows amino acids (sticks) chosen for mutational analysis of Nsp16 (orange and burgundy) and their corresponding main interaction partners in Nsp10 (pale cyan). (D) B2H results showing effects of Nsp16 substitutions on its interactions with Nsp10 and with Nsp15. Amino acid substitutions introduced into Nsp16 are given in the box. (B,D) Indicated ORFs are fused either to the α NTD (indicated as α) or to full-length λ CI. α and λ CI negative controls express full-length α and full length λ CI, respectively. Bar graphs show the averages of three biological replicates (n=3) and β -galactosidase activities are given in Miller units. Error bars indicate the standard deviation. Values indicated with asterisks are significantly different from the WT. ns: not significant; *: P<0.05; **: P<0.01; ****: P<0.0001 (One-way ANOVA with Dunnett's multiple comparison test). Black dashed lines in A and C represent hydrogen bonds.

Fig. 5: Interaction of spike RBD and ACE2 in an oxidizing *E. coli* strain. (A) Bacterial two-hybrid assays of (A) spike domains (as listed in Supplementary Fig. 7) tested against ACE2 in BLS148, (B) indicated spike RBD cysteine mutants tested against ACE2 in BLS148 and B2H or (C) indicated spike RBD circulating variants tested against ACE2 in BLS148. FL: full-length, NTD: N-terminal domain; RBD: receptor binding domain; CTD: C-terminal domain (with or without transmembrane domain (TMD)), Ecto: Ectodomain starting either at aa 13 or 16. (D) Schematic depicting amino acid substitutions present in each of three RBD variants tested. The measured effect of each substitution on ACE2 binding is indicated with a dash (no effect), a downward pointing arrow (weakened binding) or an upward pointing arrow (strengthened binding). (A-C) spike domains or RBD mutant variants were fused to the α NTD (indicated as α) and ACE2 was fused to full-length λ CI. α and λ CI negative controls express full-length α and full-length λ CI, respectively. Bar graphs show (A) one biological replicate or (B,C) the averages of three biological replicates (n=3) and β -galactosidase activities are given in Miller units. Note: results depicted in (C) have been confirmed in a total of seven independent experiments, one of which is shown here. Error bars indicate the standard deviation. Values indicated with asterisks are significantly different from the negative control. ns: not significant; *: P<0.05; **: P<0.01; ****: P<0.0001 (Two-way ANOVA with Turkey's multiple comparison test). Western blot analysis indicated that the spike RBD mutants used in (B) and (C) are present at intracellular levels comparable to the wild-type RBD, ruling out protein instability as a cause for the observed effects (Supplementary Figs. 8 and 9).

Supplementary Figure Legends

Supplementary Fig. 1: Fusion constructs of positive B2H interactions. List of all B2H-identified SARS-CoV-2 PPIs. Green-shaded rectangles indicate the plasmid from which Protein A (first-mentioned protein in the left column) is produced to elicit a positive interaction with Protein B encoded by the other plasmid. When an interaction of Protein A and Protein B was identified regardless of the encoding plasmid, rectangles are shaded green in the column “both”.

Supplementary Fig. 2: Medium-to-weak SARS-CoV-2 protein-protein interactions identified B2H assays. Shown are two-hybrid data for medium-to-weak interactions (Miller unit values between 2- and 5-fold above the negative control Miller unit value). Indicated ORFs are fused either to the α NTD (indicated as α) or to full-length λ CI (indicated as CI). α and λ CI negative controls express full-length α and full-length λ CI, respectively. The interaction of domain 4 of the RNAP σ^{70} subunit (fused to the α NTD) with the flap domain of the RNAP β subunit (fused to λ CI) served as a positive control (pos) [81,82]. Bar graphs show the averages of three biological replicates (n=3) and β -galactosidase activities are given in Miller units. Error bars indicate the standard deviation. Values indicated with asterisks are significantly different from the negative control. ***: P<0.001; ****: P<0.0001 (One-way ANOVA with Turkey's multiple comparison test).

Supplementary Fig. 3: Comparison of B2H with Y2H and co-IP data. Interaction matrix showing all SARS-CoV-2 PPIs identified with the B2H assay (this study) or with the Y2H and co-IP assays [6]. Squares designating PPIs identified solely by the B2H assay are colored purple and contain a white disc, whereas squares designating PPIs identified solely by the Y2H assay or by co-IP experiments are colored red and blue, respectively. Squares designating interactions that were identified by two or three of the assays contain the respective colors as indicated in the key at the left side of the matrix.

Supplementary Fig. 4: Comparison of SARS-CoV-2 B2H data with SARS-CoV-1 two-hybrid data. Interaction matrix showing the sixteen PPIs identified with the B2H assay (this study) and indicating which of these PPIs were also identified in at least one of three previous SARS-CoV-1 two hybrid studies, including two Y2H analyses [7,27] and one mammalian two-hybrid analysis [26]. Squares designating PPIs identified solely by the B2H assay are colored purple and contain a white disc. Coloring within the central disc designates a PPI that was also identified in one or two of the SARS-CoV-1 two-hybrid analyses (von Brunn *et al.* [7], orange; Imbert *et al.* [27], yellow; Pan *et al.* [26], cyan). Note that none of the PPIs were identified in all three SARS-CoV-1 analyses.

Supplementary Fig. 5: Western blot analysis showing intracellular levels of Nsp10, Nsp14 and Nsp16 fusion proteins. (top) Anti- α NTD and (bottom) anti- λ CI western blot of cell lysates taken from over-night cultures of cells used for B2H analysis shown in **Fig. 4B**. Samples in lanes 1-5 are from cells producing the indicated λ CI-Nsp10 fusion protein or λ CI (see key) and the α -Nsp16 fusion protein, whereas samples in lanes 10-14 are from cells producing the indicated λ CI-Nsp10 fusion protein or λ CI and the α -Nsp14 fusion protein. Samples in lanes 6-9 are from cells producing the indicated λ CI-Nsp10 fusion protein and full-length α . We note that substitutions D29A+S33A appeared to be mildly destabilizing, whereas substitutions F16A+F19A+V21A appeared to be mildly stabilizing.

Supplementary Fig. 6: Western blot analysis showing intracellular levels of Nsp10, Nsp15 and Nsp16 fusion proteins. (top) Anti- α NTD and (bottom) anti- λ CI western blot of cell lysates taken from over-night cultures of cells used for the subsequent B2H analysis shown in **Fig. 4D**. Samples in lanes 1-5 are from cells producing the indicated α -Nsp16 fusion protein or α (see key) and the λ CI-Nsp10 fusion protein, whereas samples in lanes 10-14 are from cells producing the indicated α -Nsp16 fusion protein or α and the λ CI-Nsp15 fusion protein. Samples in lanes 6-9 are from cells producing the indicated α -Nsp16 fusion protein and full-length λ CI. Lanes indicated with "X" are not discussed in the current manuscript but were not cut from the blot to avoid excessive manipulations of the original image. Note: Native, chromosomally encoded full-length α is detected in all samples.

Supplementary Fig. 7: Domains of the SARS-CoV-2 spike protein. Depiction of SARS-CoV-2 spike domains, including the signal peptide (SP, predicted from aa 1-13 or 1-16), the N-terminal domain (NTD, aa 1-330), the receptor binding domain (RBD, aa 331-521), the C-terminal domain (CTD, aa 522-1273) and the transmembrane domain (TMD, aa 1202-1273). The table lists the spike domains that were produced in *E. coli* (as B2H fusion proteins) and tested for interaction with ACE2, their precise corresponding loci on the SARS-CoV-2 genome, and the amino acids encoded by each test domain.

Supplementary Fig. 8: Western blot analysis showing intracellular levels of spike RBD fusion proteins in oxidizing vs. reducing *E. coli* test strains. (top) Anti- α NTD and (bottom) anti- λ CI Western blot of cell lysates taken from over-night cultures of BLS148 or B2H cells used for the subsequent two-hybrid analyses shown in **Fig. 5B**. Samples in lanes 1-5 and 10-14 are from BLS148 cells and B2H cells, respectively, producing the indicated α -RBD fusion protein or α (see key) and the λ CI-ACE2 fusion protein, whereas samples in lanes 6-9 and 15-18 are from BLS148 cells and B2H cells, respectively, producing the indicated α -RBD fusion protein and full-length λ CI. Lanes indicated with "X" are not discussed in the current manuscript but were not cut from the blot to avoid excessive manipulations of the original image. White dotted line indicates stitched image where extraneous material was removed. Note: Native, chromosomally encoded full-length α is detected in all samples.

Supplementary Fig. 9: Western blot analysis showing intracellular levels of spike RBD mutants. (top) Anti- α -NTD and (bottom) anti- λ CI western blot of cell lysates taken from over-night cultures of BLS148 cells used for the subsequent two-hybrid analysis shown in **Fig. 5C**.

855 Samples in lanes 1-9 are from cells producing the indicated α -RBD fusion protein or α (see key)
 856 and the λ CI-ACE2 fusion protein, whereas samples in lanes 10-17 are from cells producing the
 857 indicated α -RBD fusion protein and full-length λ CI. Note: Native, chromosomally encoded full-
 858 length α in all samples.

859 **Supplementary Table Legends**

860 **Supplementary Table 1:** List of (A) strains and plasmids, and (B) oligonucleotide primers used
 861 in this study.

Acknowledgments

We thank Eleanor Fleming, Zoë Feder, Kemardo Henry, EmilyKate McDonough, Hanif Vahedian Movahed and Simon Dove for valuable discussion; Simon Dove and Jonathan Abraham for comments on the manuscript; and Sydney Rosa Teixeira for technical support. BLS, PD and AH were supported by a “Maximizing Investigators' Research Award” (MIRA; No. R35GM136247) awarded to AH.

Author contribution

AH and BLS designed the study. BLS performed the experimental work with support from PD. GG analyzed crystal structure data and provided predictions for the mutational screens. BLS and AH drafted the manuscript with contributions from all coauthors.

Competing interests

The authors declare no competing interests.

Data availability

All data generated during and/or analyzed during the current study are either provided within the manuscript or are available from the corresponding authors upon reasonable request.

Material and Methods

Bacterial strains and growth conditions

E. coli strains MAX Efficiency™ DH5αF'IQ (Invitrogen) and NEB® 5-alpha F'IQ (New England Biolabs, NEB) were used for routine cloning procedures and chemically competent *E. coli* were transformed with plasmid DNA by the standard heat shock procedure. FW102 O_L2–62 and BLS148 strains were used for bacterial two-hybrid assays. All strains listed in Supplementary Table 1A were grown in LB medium containing the appropriate antibiotics at standard concentrations. BLS148 was created by P1 phage transduction of $\Delta lacZYA::kmR$ from strain TB12 (P1 phage lysates were a gift from Thomas Bernhardt, Harvard Medical School) to SHuffle® Express (NEB) according to a protocol established by Robert T. Sauer (Massachusetts Institute of Technology; protocol available at: https://openwetware.org/wiki/Sauer:P1vir_phage_transduction), generating BLS128. Deletion of *lacZ* in BLS128 was verified by colony PCR (using primers oBLS107+oBLS108 targeting *lacZ* to test for absence of *lacZ* and primers oBLS109+oBLS110 targeting *motA* and primers oBLS138+oBLS139 targeting *cyaA* as control reactions). Next, TSS competent BLS128 cells were created according to [83], transformed with pCP20 (encoding the yeast Flp recombinase gene to flip out the kanamycin resistance gene) and grown over night at 30 °C on LB plates containing carbenicillin (100 µg/ml; Carb100). The next day, 10 colonies were picked and re-streaked on LB plates without antibiotics and then grown over night at 42 °C. From each of those strains a single colony was picked and re-streaked on LB plates containing either Carb100, kanamycin (20 µg/ml; Km20) or spectinomycin (50 µg/ml, Sp50) and grown over night at 30 °C. A single Sp50 resistant but Carb100 and Km20 sensitive colony was picked and re-verified by streaking on the same growth plates. This strain that had lost the *kmR* resistance cassette was then designated BLS133. Finally, the β-galactosidase reporter present on the F' was introduced into BLS133 by mating with strain FW102 O_L2–62 [84]. For this, both BLS133

and FW102 O_L2–62 were grown over night at 37 °C in LB Sp50 or Km20, respectively, and then streaked on top of each other on the same LB plate. After about 8 hours at 37 °C cells were resuspended in LB and plated in serial dilutions on LB plates containing Sp50, Km20 and X-gal (40 µg/ml; X-gal40) and then grown over night at 37 °C. A blue colony was picked and re-verified by streaking again on a LB plate containing Sp50, Km20 and X-gal40, creating BLS148, a bacterial two-hybrid-compatible SHuffle[®] Express strain.

Plasmid construction

All plasmids generated in this study (see Supplementary Table 1A) were either constructed using standard restriction enzyme-based cloning procedures or by Gibson assembly. Gibson assembly was performed for 1 h at 50 °C by default. Primers employed for plasmid construction are listed in Supplementary Table 1B. Plasmid sequence integrity was verified by Sanger sequencing from Genewiz or Quintarabio (both Boston, MA, USA). Unless otherwise stated, all sequence templates, except for Nsp11, were ordered as *E. coli* codon-optimized gene fragments from Twist Bioscience (San Francisco, CA, USA).

Except for spike, Nsp2, Nsp3, RNA-Polymerase (Nsp12) and helicase (Nsp13), all full-length codon-optimized gene fragments were digested with NotI+BamHI, purified by DNA Clean & Concentrator kit (Zymo Research) and then ligated into 50 ng NotI+BamHI-digested pBRα or pACλCI using T4 ligase (NEB) according to standard protocols generating the plasmids listed in Supplementary Table 1A.

Spike: For pS63, the spike full-length (FL) sequence was amplified from *E. coli* codon-optimized gene fragments by SARS_67+SARS_68 and cloned into NotI+BamHI-digested pBRα by Gibson assembly. For pS64, the NTD sequence was amplified from pS63 by SARS_67+SARS_69 and then cloned into NotI+BamHI-digested pBRα by Gibson assembly. For pS65, the RBD sequence was amplified from pS63 by SARS_70+SARS_71 and then cloned into NotI+BamHI-

926 digested pBR α by Gibson assembly. For pS66, the CTD sequence was amplified from pS63 by
 927 SARS_68+SARS_72 and then cloned into NotI+BamHI-digested pBR α by Gibson assembly.
 928 For pS67, the Ectodomain (aa 13-1213) was amplified from pS63 by SARS_73+SARS_74 and
 929 then cloned into NotI+BamHI-digested pBR α by Gibson assembly. For pS68, the Ectodomain
 930 (aa 16-1213) was amplified from pS63 by SARS_74+SARS_75 and then cloned into
 931 NotI+BamHI-digested pBR α by Gibson assembly. pS70 was generated by site-directed
 932 mutagenesis (SDM; see below) using primers SARS_17+SARS_76 and pS63 as a template.
 933 For pS72, FL spike was amplified from pS63 by SARS_77+SARS_78 and then cloned into
 934 NotI+BamHI-digested pAC λ CI by Gibson assembly. For pS73, the NTD sequence was amplified
 935 from pS63 by SARS_77+SARS_79 and then cloned into NotI+BamHI-digested pAC λ CI by
 936 Gibson assembly. For pS74, the RBD sequence was amplified from pS63 by
 937 SARS_80+SARS_81 and then cloned into NotI+BamHI-digested pAC λ CI by Gibson assembly.
 938 For pS75, the CTD sequence was amplified from pS63 by SARS_78+SARS_82 and then cloned
 939 into NotI+BamHI-digested pAC λ CI by Gibson assembly. For pS76, the Ectodomain (aa 13-
 940 1213) was amplified from pS63 by SARS_83+SARS_84 and then cloned into NotI+BamHI-
 941 digested pAC λ CI by Gibson assembly. For pS77, the Ectodomain (aa 16-1213) was amplified
 942 from pS63 by SARS_84+SARS_85 and then cloned into NotI+BamHI-digested pAC λ CI by
 943 Gibson assembly. pS79 was generated by SDM using primers SARS_17+SARS_86 and pS63
 944 as a template.

945 Nsp2: The Nsp2 sequence was ordered as two single gene fragments, which were further
 946 amplified by PCR using primers SARS_109+SARS_110 or SARS_111+SARS_112 and then
 947 cloned into NotI+BamHI-digested pBR ω GP by Gibson assembly, creating pS85. Next, the whole
 948 Nsp2 open reading frame (ORF) was cut from pS85 by NotI+BamHI and inserted into 50 ng

NotI+BamHI-digested pBR α or pAC λ CI using T4 ligase (NEB) according to standard protocols, creating pS179 and pS180, respectively.

Nsp3: The Nsp3 sequence was ordered as four single gene fragments, which were further amplified by PCR using primers SARS_115+SARS_116, SARS_117+SARS_118, SARS_119+SARS_120 or SARS_121+SARS_122 and then cloned into NotI+BamHI-digested pBR ω GP by Gibson assembly, creating pS89. Next, the whole Nsp3 open reading frame (ORF) was cut from pS89 by NotI+BamHI and inserted into 50 ng NotI+BamHI-digested pBR α or pAC λ CI using T4 ligase (NEB) according to standard protocols, creating pS181 and pS182, respectively.

RNA-Polymerase (Nsp12): The RNA-Polymerase sequence was ordered as three single gene fragments, which were further amplified by PCR using primers SARS_131+SARS_132, SARS_133+SARS_134 or SARS_135+SARS_136 and then cloned into NotI+BamHI-digested pBR ω GP by Gibson assembly, creating pS173. Next, the whole Nsp3 open reading frame (ORF) was cut from pS89 by NotI+BamHI and inserted into 50 ng NotI+BamHI-digested pBR α or pAC λ CI using T4 ligase (NEB) according to standard protocols, creating pS181 and pS182, respectively.

helicase (Nsp13): The helicase sequence was ordered as two single gene fragments, which were further amplified by PCR using primers SARS_125+SARS_126 or SARS_127+SARS_128 and then cloned into NotI+BamHI-digested pBR ω GP by Gibson assembly, creating pS169. Next, the whole Nsp2 open reading frame (ORF) was cut from pS85 by NotI+BamHI and inserted into 50 ng NotI+BamHI-digested pBR α or pAC λ CI using T4 ligase (NEB) according to standard protocols, creating pS221 and pS222, respectively.

ACE2: The ACE2 N-terminal peptidase domain (aa 19-615) was ordered as a single gene fragment and then further amplified by PCR using primers SARS_264+SARS_265 or SARS_266+SARS_267 and then cloned into 50 ng NotI+BamHI-digested pBR α or pAC λ CI by Gibson assembly, creating pS260 and pS261, respectively.

Nsp11 was cloned into pBR α or pAC λ CI as annealed primers. For this, 10 μ l of 100 μ M SARS_139 and SARS_140 primers were mixed with 1 μ l T4 Polynucleotide kinase (PNK; NEB) in 1x PNK reaction buffer (NEB). The reaction mix was placed in a BioRad T100 Thermal cycler, incubated for 30 min at 37 °C, inactivated for 5 min at 95 °C and then cooled to 4 °C at a 0.1 °C/s ramp rate. The annealed oligos were diluted 1:50 and then ligated into 50 ng NotI+BamHI-digested pBR α or pAC λ CI using T4 ligase (NEB), generating pS197 and pS198, respectively.

Plasmid mutagenesis

Plasmid mutagenesis to create SARS-CoV-2 mutant genes was achieved using the Q5[®] Site-Directed Mutagenesis (SDM) Kit according to the manufacturer's instructions (NEB) or by using Gibson assembly with mutations introduced into the complementary overhang regions of the primer sequences. For the Gibson assembly, plasmids were amplified with the indicated primer pairs and 1 μ l of the resulting PCR reaction was then ligated by Gibson assembly in a 10 μ l reaction volume.

pS254 was generated by SDM using primers SARS_253+SARS_254 and plasmid pS215 as a template. pS256 was generated by SDM using primers SARS_256+SARS_257 and plasmid pS215 as a template. pS257 was generated by SDM using primers SARS_256+SARS_257 and plasmid pS254 as a template. pS262 was generated by Gibson assembly using primers SARS_268+SARS_269 and plasmid pS196 as a template. pS263 was generated by Gibson assembly using primers SARS_270+SARS_271 and plasmid pS196 as a template. pS264 was generated by Gibson assembly using primers SARS_272+SARS_273 and plasmid pS196 as a

template. pS267 was generated by Gibson assembly using primers SARS_280+SARS_281 and plasmid pS65 as a template. pS271 was generated by Gibson assembly using primers SARS_287+SARS_288 and plasmid pS65 as a template. pS272 was generated by Gibson assembly using primers SARS_289+SARS_290 and plasmid pS65 as a template. pS273 was generated by Gibson assembly using primers SARS_289+SARS_290 and plasmid pS271 as a template. pS275 was generated by Gibson assembly using primers SARS_295+SARS_296 and plasmid pS65 as a template. pS276 was generated by Gibson assembly using primers SARS_291+SARS_292 and plasmid pS65 as a template. pS277 was generated by Gibson assembly using primers SARS_293+SARS_294 and plasmid pS65 as a template. pS278 was generated by Gibson assembly using primers SARS_291+SARS_292 and plasmid pS267 as a template. pS279 was generated by Gibson assembly using primers SARS_293+SARS_294 and plasmid pS267 as a template. pS280 was generated by Gibson assembly using primers SARS_293+SARS_294 and plasmid pS278 as a template.

β-galactosidase assays

β-galactosidase assays to study the SARS-CoV-2 interactome were performed essentially as described previously [85]. In particular, pBRα and pACλCI plasmids containing the indicated inserts were co-transformed into FW102 O_L2–62 by the heat shock procedure. Briefly, 2 μl of each plasmid (1:10 dil.) were mixed with 20 μl chemically competent FW102 O_L2–62 cells, incubated on ice in 96-well PCR plates (VWR) for 30 min and then heat-shocked for 1 min at 42 °C in a BioRad T100 Thermal cycler. Cells were placed on ice for 5 min, recovered in 80 μl fresh LB medium and then incubated at 37 °C for 1 h (Please note: we found that commercially available premixed LB drastically reduces transformation efficiency and also subsequent overnight culture growth; we thus recommend using non-premixed LB medium instead). The 96-well plates were sealed with Rayon Films (VWR) to allow proper aeration and prevent contamination. Afterwards, 50 μl of transformed cells were transferred to 2 ml deep well plates

containing 500 µl LB Carb100, chloramphenicol (25 µg/ml; Cm25), Km20 and 5 µM IPTG and grown over night at 37 °C, 800 rpm. The next day, 4 µl over-night culture was transferred to 96-well flat bottom microtiter plates containing 200 µl LB Carb100, Cm25, Km20 and 20 µM IPTG and grown until approx. OD₆₀₀ 0.15-0.2 (measured in a VERSA Max microplate reader, Molecule Devices, San Jose, CA, USA). Then, 20 µl lysis solution (for one 96-well plate mix: 1.2 ml PopCulture[®] Reagent (MilliporeSigma, MA, USA), 2.5 µl 400 U/µl rLysozyme[™] (MilliporeSigma, MA, USA) and 1.25 µl Benzonase[®] Nuclease (MilliporeSigma, MA, USA)) was added to the cells and incubated for at least 30 min at 37 °C and 800 rpm (longer incubation times were found to not negatively affect the experimental results). Afterwards, 30 µl lysed cell suspension was added to a fresh 96-well flat-bottom microtiter plate containing 150 µl Z-buffer/ONPG solution (60 mM Na₂HPO₄, 40 mM NaH₂PO₄, 10 mM KCl, 1 mM MgSO₄, 1 mg/ml ortho-Nitrophenyl-β-galactoside (ONPG)) and OD₄₂₀ values were recorded in a VERSA Max microplate reader (Molecule Devices, San Jose, CA, USA). β-galactosidase activity in Miller units was then calculated as described previously [85].

β-galactosidase assays to study the RBD-ACE2 interaction were performed as follows. Strain BLS148 was transformed with the appropriate plasmids, as described in the preceding paragraph. Upon recovery of the transformed cells for 1 h at 37 °C, 50 µl cells were then transferred to 500 µl LB Carb100, Km20, Cm25 and 50 µM IPTG and grown for approx. 20 h at 30 °C and 800 rpm. Subsequently, 15 µl cells were transferred to 185 µl LB medium in 96-well microtiter plates, combined with 20 µl lysis solution (for one 96-well plate: 1.2 ml PopCulture[®] Reagent (MilliporeSigma, MA, USA), 5.0 µl 400U/µl rLysozyme[™] (MilliporeSigma, MA, USA) and 2.5 µl Benzonase[®] Nuclease (MilliporeSigma, MA, USA)) and incubated for at least 30 min at 30 °C, 800 rpm. All subsequent steps were then performed as described above.

1044 *Western blot analysis*

1045 To verify the production of the respective fusion proteins, western blots of cell lysates from over-
1046 night cultures were performed. For this, co-transformed cells were grown in the indicated IPTG
1047 concentration over-night in 550 µl total volume in 2 ml deep well plates at 30 or 37 °C, 800 rpm.
1048 The next day, OD₆₀₀ values were recorded and 500 µl cells were pelleted by centrifugation (1
1049 min, 21,000 x g, room temperature (RT)) and either stored at -80 °C or directly processed. Cell
1050 pellets were then resuspended in lysis buffer (BugBuster® Protein Extraction Reagent
1051 (MilliporeSigma, MA, USA) supplemented with 1x cOmplete™, EDTA-free Protease Inhibitor
1052 Cocktail (MilliporeSigma, MA, USA), 1 U/µl rLysozyme™ (MilliporeSigma, MA, USA; final
1053 concentration) and 0.5 U/µl Benzonase® Nuclease (MilliporeSigma, MA, USA, final
1054 concentration)). The amount of lysis buffer for each cell pellet was calculated as follows: µl lysis
1055 buffer = OD₆₀₀ x ml of culture pelleted x 60. Cells were lysed for 30 min at RT in an overhead
1056 shaker. Next, lysed cells were mixed 1:5 in PBS (10.14 mM Na₂HPO₄, 1.76 mM NaH₂PO₄, 2.7
1057 mM KCl, 137 mM NaCl; pH 7.4, Boston Bioproducts, MA, USA) and then incubated in 1 x
1058 Laemmli SDS sample buffer (Boston Bioproducts, MA, USA) at 95 °C for 10 min. 10 µl of the
1059 resulting solution was then applied to either 4–12% Criterion™ XT Bis-Tris Protein Gels
1060 (BioRad, Hercules, CA, USA) or NuPAGE™ 4 - 12% Bis-Tris Mini Protein Gels (Thermo Fisher
1061 Scientific, MA, USA). Upon gel separation, proteins were transferred to Amersham Protran 0.45
1062 NC nitrocellulose membranes (Cytiva, MA, USA) using a Trans-Blot Turbo Transfer System
1063 (BioRad Hercules, CA, USA), blocked in blocking buffer (TBST: 50 mM Tris-HCl, 150 mM NaCl,
1064 pH 7.4, 0.1 % Tween-20 supplemented with 5% non-fat dry milk) for 30 min at RT and then
1065 incubated with mouse anti-a-NTD and rabbit anti-CI primary antibodies (both 1:3,000 dil.) in
1066 blocking buffer for 1 h at RT. After washing with TBST, blots were incubated with IRDye®
1067 680RD goat anti-mouse and IRDye® 800CW goat anti-rabbit (both 1:10,000 dil.; LI-COR

Biosciences, NE, USA) in blocking buffer for 1 h at RT in the dark. After washing with TBST, proteins were then detected using a ChemiDoc MP system (BioRad. Hercules, CA, USA).

Protein crystal structure analysis

Interfaces of two protein complexes, SARS-CoV-2 Nsp16-Nsp10 (PDB ID: 6W4H [31]) and SARS-CoV-1 Nsp10-Nsp14 (PDB ID: 5NFY [29]), were analyzed using PDBePISA software (*insert ref 20*). Amino acids involved in hydrogen bond formation or substantially contributing to hydrophobic contacts in each complex were subjected to alanine mutagenesis and tested in B2H assays. Structural images were prepared using PyMOL software (Schrodinger, LLC. 2010. The PyMOL Molecular Graphics System, Version 2.4.1).

Statistical analysis

Presentation of bacterial two-hybrid data and statistical analysis using one-way or two-way ANOVA with Tukey's or Dunnett's multiple comparison test was done using GraphPad Prism (v. 9.1.2; San Diego, CA, USA).

B

ORF	Genomic locus (nt range)	AA
Nsp1	266-805	188
Nsp2	806-2719	636
Nsp3	2720-8554	1,945
Nsp4	8555-10054	500
Nsp5	10055-10972	306
Nsp6	10973-11842	290
Nsp7	11843-12091	83
Nsp8	12092-12685	198
Nsp9	12686-13024	113
Nsp10	13025-13441	139
Nsp11	13442-13483	13
Nsp12 (RNA-Polymerase)	13442-16236	932
Nsp13 (Helicase)	16237-18039	601
Nsp14 (3'-5' Exonuclease)	18040-19620	527
Nsp15 (endoRNase)	19621-20658	346
Nsp16 (Methyltransferase)	20659-21555	298
Spike (S) ectodomain	21607-25201	1,201
3a	25393-26220	275
E	26245-26472	75
M	26525-27191	222
6	27202-27387	61
7a	27397-27759	121
7b	27756-27887	43
8	27894-28259	121
N	28274-29533	419
10	29558-29674	38

	Nsp1	Nsp2	Nsp3	Nsp4	Nsp5	Nsp6	Nsp7	Nsp8	Nsp9	Nsp10	Nsp11	Nsp12	Nsp13	Nsp14	Nsp15	Nsp16	3a	6	7a	7b	8	10	S	M	N	E
Nsp1																										
Nsp2																										
Nsp3																										
Nsp4																										
Nsp5																										
Nsp6																										
Nsp7																										
Nsp8																										
Nsp9																										
Nsp10																										
Nsp11																										
Nsp12																										
Nsp13																										
Nsp14																										
Nsp15																										
Nsp16																										
3a																										
6																										
7a																										
7b																										
8																										
10																										
S																										
M																										
N																										
E																										

Interaction Self-interaction